thiamine has been researched along with Disease Exacerbation in 17 studies
thiamine(1+) : A primary alcohol that is 1,3-thiazol-3-ium substituted by (4-amino-2-methylpyrimidin-5-yl)methyl, methyl and 2-hydroxyethyl groups at positions 3, 4 and 5, respectively.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Shoshin beriberi is a fulminant form of cardiac beriberi caused by thiamine deficiency." | 7.80 | A case of shoshin beriberi presenting as cardiogenic shock with diffuse ST-segment elevation, which dramatically improved after a single dose of thiamine. ( Kang, WC; Kim, J; Kim, JH; Kim, SJ; Kim, SW; Park, S, 2014) |
| " Although thiamine deficiency is a possible cause of this neuropathy, the pathogenesis still remains to be clarified." | 7.71 | Postgastrectomy polyneuropathy with thiamine deficiency. ( Hattori, N; Hirayama, M; Ichimura, M; Ito, H; Ito, S; Koike, H; Misu, K; Nagamatsu, M; Sasaki, I; Sobue, G, 2001) |
| "Acute encephalopathy with biphasic seizures and late reduced diffusion (AESD) is the most prevalent encephalopathy in Japanese children." | 5.51 | Early administration of vitamins B1 and B6 and l-carnitine prevents a second attack of acute encephalopathy with biphasic seizures and late reduced diffusion: A case control study. ( Fukui, KO; Ishiguro, A; Kashii, H; Kubota, M; Terashima, H, 2019) |
| "Wernicke encephalopathy is an acute, reversible neuropsychiatric emergency due to thiamine deficiency." | 4.90 | Thiamine in the treatment of Wernicke encephalopathy in patients with alcohol use disorders. ( Dore, G; Latt, N, 2014) |
| "Shoshin beriberi is a fulminant form of cardiac beriberi caused by thiamine deficiency." | 3.80 | A case of shoshin beriberi presenting as cardiogenic shock with diffuse ST-segment elevation, which dramatically improved after a single dose of thiamine. ( Kang, WC; Kim, J; Kim, JH; Kim, SJ; Kim, SW; Park, S, 2014) |
| " Thiamine deficiency (TD) in rats is a model for the study of cellular and molecular mechanisms that lead to selective neuronal loss caused by chronic oxidative deficits." | 3.76 | Neurodegeneration in thiamine deficient rats-A longitudinal MRI study. ( Assaf, Y; Biton, IE; Dror, V; Eliash, S; Fattal-Valevski, A; Rehavi, M, 2010) |
| " Although thiamine deficiency is a possible cause of this neuropathy, the pathogenesis still remains to be clarified." | 3.71 | Postgastrectomy polyneuropathy with thiamine deficiency. ( Hattori, N; Hirayama, M; Ichimura, M; Ito, H; Ito, S; Koike, H; Misu, K; Nagamatsu, M; Sasaki, I; Sobue, G, 2001) |
| "The primary clinical outcome was the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog)." | 2.94 | Benfotiamine and Cognitive Decline in Alzheimer's Disease: Results of a Randomized Placebo-Controlled Phase IIa Clinical Trial. ( Bettendorff, L; Chen, H; Chen, Z; Cirio, R; Flowers, SA; Fonzetti, P; Franchino-Elder, J; Gerber, LM; Gibson, GE; Grandville, T; Habeck, C; Hirsch, JA; Jordan, B; Luchsinger, JA; Schupf, N; Stern, Y; Xu, H, 2020) |
| "This relation could be modified by genetic susceptibility, particularly related to the C3 genotype." | 2.82 | Dietary folate, B vitamins, genetic susceptibility and progression to advanced nonexudative age-related macular degeneration with geographic atrophy: a prospective cohort study. ( Merle, BM; Rosner, B; Seddon, JM; Silver, RE, 2016) |
| "Acute encephalopathy with biphasic seizures and late reduced diffusion (AESD) is the most prevalent encephalopathy in Japanese children." | 1.51 | Early administration of vitamins B1 and B6 and l-carnitine prevents a second attack of acute encephalopathy with biphasic seizures and late reduced diffusion: A case control study. ( Fukui, KO; Ishiguro, A; Kashii, H; Kubota, M; Terashima, H, 2019) |
| "A 33-year-old woman with Wernicke's encephalopathy (WE) due to poor oral intake after allogeneic stem cell transplantation for acute myeloid leukemia showed a sequential development of bilateral gaze-evoked nystagmus (GEN), rightward gaze palsy, and upbeat nystagmus." | 1.38 | Evolution of abnormal eye movements in Wernicke's encephalopathy: correlation with serial MRI findings. ( Kim, JS; Kim, K; Lee, YB; Park, HM; Park, KH; Shin, DH; Shin, DJ, 2012) |
| "Thiamine is an essential cofactor for several important enzymes involved in brain oxidative metabolism, such as the alpha-ketoglutarate dehydrogenase complex (KGDHC), pyruvate-dehydrogenase complex (PDHC), and transketolase." | 1.31 | Cerebrospinal fluid levels of thiamine in patients with Alzheimer's disease. ( de Bustos, F; Fernández-Vivancos, E; Gómez-Escalonilla, C; Hernánz, A; Jiménez-Jiménez, FJ; Medina, S; Molina, JA; Sayed, Y, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (29.41) | 29.6817 |
| 2010's | 10 (58.82) | 24.3611 |
| 2020's | 2 (11.76) | 2.80 |
| Authors | Studies |
|---|---|
| Gibson, GE | 1 |
| Luchsinger, JA | 1 |
| Cirio, R | 1 |
| Chen, H | 1 |
| Franchino-Elder, J | 1 |
| Hirsch, JA | 1 |
| Bettendorff, L | 1 |
| Chen, Z | 1 |
| Flowers, SA | 1 |
| Gerber, LM | 1 |
| Grandville, T | 1 |
| Schupf, N | 1 |
| Xu, H | 1 |
| Stern, Y | 1 |
| Habeck, C | 1 |
| Jordan, B | 1 |
| Fonzetti, P | 1 |
| Tsui, E | 1 |
| Tauber, J | 1 |
| Barbazetto, I | 1 |
| Gelman, SK | 1 |
| Macchione, N | 1 |
| Bernardini, P | 1 |
| Piacentini, I | 1 |
| Mangiarotti, B | 1 |
| Del Nero, A | 1 |
| Fukui, KO | 1 |
| Kubota, M | 1 |
| Terashima, H | 1 |
| Ishiguro, A | 1 |
| Kashii, H | 1 |
| Latt, N | 1 |
| Dore, G | 1 |
| Kim, J | 1 |
| Park, S | 1 |
| Kim, JH | 1 |
| Kim, SW | 1 |
| Kang, WC | 1 |
| Kim, SJ | 1 |
| Merle, BM | 1 |
| Silver, RE | 1 |
| Rosner, B | 1 |
| Seddon, JM | 1 |
| Freire-Aragón, MD | 1 |
| Fernández Delgado, E | 1 |
| Carbajal-Guerrero, J | 1 |
| Ribera-Rubiales, G | 1 |
| Flabeau, O | 1 |
| Foubert-Samier, A | 1 |
| Meissner, W | 1 |
| Tison, F | 1 |
| Helbok, R | 1 |
| Beer, R | 1 |
| Engelhardt, K | 1 |
| Broessner, G | 1 |
| Lackner, P | 1 |
| Brenneis, C | 1 |
| Pfausler, B | 1 |
| Schmutzhard, E | 1 |
| Dror, V | 1 |
| Eliash, S | 1 |
| Rehavi, M | 1 |
| Assaf, Y | 1 |
| Biton, IE | 1 |
| Fattal-Valevski, A | 1 |
| Richardson, AD | 1 |
| Moscow, JA | 1 |
| Kornienko, AM | 1 |
| Kornienko, RA | 1 |
| Kim, K | 1 |
| Shin, DH | 1 |
| Lee, YB | 1 |
| Park, KH | 1 |
| Park, HM | 1 |
| Shin, DJ | 1 |
| Kim, JS | 1 |
| Molina, JA | 1 |
| Jiménez-Jiménez, FJ | 1 |
| Hernánz, A | 1 |
| Fernández-Vivancos, E | 1 |
| Medina, S | 1 |
| de Bustos, F | 1 |
| Gómez-Escalonilla, C | 1 |
| Sayed, Y | 1 |
| Ndiaye, M | 1 |
| Sène-Diouf, F | 1 |
| Diop, AG | 1 |
| Ndao, AK | 1 |
| Diagne, M | 1 |
| Thiam, A | 1 |
| Ndiaye, MM | 1 |
| Ndiaye, IP | 1 |
| Koike, H | 1 |
| Misu, K | 1 |
| Hattori, N | 1 |
| Ito, S | 1 |
| Ichimura, M | 1 |
| Ito, H | 1 |
| Hirayama, M | 1 |
| Nagamatsu, M | 1 |
| Sasaki, I | 1 |
| Sobue, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Benfotiamine in Alzheimer's Disease: A Pilot Study[NCT02292238] | Phase 2 | 71 participants (Actual) | Interventional | 2015-02-15 | Completed | ||
| Age-Related Eye Disease Study (AREDS) and AREDS2 Follow-Up[NCT00594672] | 110 participants (Actual) | Observational | 2008-06-02 | Active, not recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"The Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) is a brief neuropsychological assessment used to assess the severity of cognitive symptoms of dementia. It is one of the most widely used cognitive scales in clinical trials and is considered to be the gold standard for assessing antidementia treatments. The ADAS-Cog range from 0 to 70, where higher scores indicate greater cognitive dysfunction." (NCT02292238)
Timeframe: Baseline, 1 year
| Intervention | score on a scale (Mean) |
|---|---|
| Benfotiamine | 1.39 |
| Placebo | 3.26 |
Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL) is a caregiver-based Activities of Daily Living (ADL) scale composed of 23 items developed for use in dementia clinical studies. It was designed to assess the patient's performance of both basic and instrumental activities of daily living such as those necessary for personal care, communicating and interacting with other people, maintaining a household, conducting hobbies and interests, as well as making judgments and decisions. The range for the total ADCS-ADL score is 0 to 78. Higher scores equate with higher functioning. (NCT02292238)
Timeframe: Baseline, 1 year
| Intervention | score on a scale (Mean) |
|---|---|
| Benfotiamine | -1.931 |
| Placebo | -3.16129 |
The AAL (Automatic Anatomical Labeling) atlas provides the taxonomy for 116 regions of interest, 90 of which capture non-cerebellar cortical regions. Signal averages from 9 cerebellar regions from each hemisphere were further averaged into one composite cerebellar region for each hemisphere, 'Cerebellum_L' and 'Cerebellum_R', which were comprised of the respective laterality averages of the regions: 'Cerebellum_Crus1 ' 'Cerebellum_Crus2 'Cerebellum_3' 'Cerebellum_4_5' 'Cerebellum_6' 'Cerebellum_7b' 'Cerebellum_8' 'Cerebellum_9' 'Cerebellum_10 '. Subsequently, these two composite regions are further combined with the bilateral paracentral lobules to provide one final composite for reference scaling. Concretely, the values from 'Cerebellum_L', 'Cerebellum_R', 'Paracentral_Lobule_L', and 'Paracentra_Lobule_R' were averaged. This final composite will serve as the denominator for the scaling operation of any ROI value prior to group-level analysis. (NCT02292238)
Timeframe: Baseline, 1 year
| Intervention | ratio (Mean) |
|---|---|
| Benfotiamine | -0.02 |
| Placebo | -0.01 |
The SRT is a standard diagnostic tool in the assessment of verbal memory. The Buschke SRT immediate total scores are compared between treated (benfotiamine) and control (placebo) groups. The immediate total score is the sum of correct responses over the 6 learning trials with scores ranging from 0 to 72. A score of 0 means severe impairment in memory. A score of 72 means there is no impairment in memory. For the purpose of determining effect over several trials between groups, the fractional change from the baseline of each group is compared. (NCT02292238)
Timeframe: Baseline, 1 year
| Intervention | score on a scale (Mean) |
|---|---|
| Benfotiamine | 0.86 |
| Placebo | -1.12 |
The CDR was developed primarily for use in persons with dementia of the Alzheimer type (the equivalent of probable Alzheimer's Disease) and can also be used to stage dementia in other illnesses as well. The scores for the multiple items are summarized in one score. The CDR examines 6 categories of cognitive functioning domains. Each domain is scored on a scale ranging from 0 to 3 (including 0.5). A CDR-SB was generated as the sum of the values in each of the 6 domains. The CDR-SB sum scores range from 0 to 18, with higher scores indicating greater cognitive impairment and a 1 point worsening is considered a clinically significant symptom change. (NCT02292238)
Timeframe: Baseline, 1 year
| Intervention | score on a scale (Mean) |
|---|---|
| Benfotiamine | 0.05 |
| Placebo | 0.22 |
The NPI assesses a wide range of behaviors encountered in dementia patients to provide a means of distinguishing frequency and severity of behavioral changes. Ten behavioral and two neuro-vegetative domains are evaluated through an interview with the caregiver. The total score ranges from 0 to 144. Higher scores suggest greater psychiatric impairment. (NCT02292238)
Timeframe: Baseline, 1 year
| Intervention | score on a scale (Mean) |
|---|---|
| Benfotiamine | 6.69 |
| Placebo | 9.23 |
1 review available for thiamine and Disease Exacerbation
| Article | Year |
|---|---|
Thiamine in the treatment of Wernicke encephalopathy in patients with alcohol use disorders.
Topics: Alcoholism; Disease Progression; Dose-Response Relationship, Drug; Early Diagnosis; Humans; Korsakof | 2014 |
3 trials available for thiamine and Disease Exacerbation
| Article | Year |
|---|---|
Benfotiamine and Cognitive Decline in Alzheimer's Disease: Results of a Randomized Placebo-Controlled Phase IIa Clinical Trial.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aniline Compounds; Apolipoprotein E4; Brain; Cognitive D | 2020 |
Flower Pollen Extract in Association with Vitamins (Deprox 500®) Versus Serenoa repens in Chronic Prostatitis/Chronic Pelvic Pain Syndrome: A Comparative Analysis of Two Different Treatments.
Topics: Adult; Aged; Disease Progression; Drug Combinations; Folic Acid; Humans; Hypertension; Male; Middle | 2019 |
Dietary folate, B vitamins, genetic susceptibility and progression to advanced nonexudative age-related macular degeneration with geographic atrophy: a prospective cohort study.
Topics: Aged; Body Mass Index; Collagen Type VIII; Complement C2; Complement C3; Complement Factor B; Comple | 2016 |
13 other studies available for thiamine and Disease Exacerbation
| Article | Year |
|---|---|
LONG-TERM MULTIMODAL IMAGING OF OCULAR FINDINGS ASSOCIATED WITH THIAMINE-RESPONSIVE MEGALOBLASTIC ANEMIA.
Topics: Anemia, Megaloblastic; Disease Progression; Electroretinography; Fluorescein Angiography; Follow-Up | 2020 |
Early administration of vitamins B1 and B6 and l-carnitine prevents a second attack of acute encephalopathy with biphasic seizures and late reduced diffusion: A case control study.
Topics: Brain Diseases; Carnitine; Case-Control Studies; Child, Preschool; Diagnosis, Differential; Disease | 2019 |
A case of shoshin beriberi presenting as cardiogenic shock with diffuse ST-segment elevation, which dramatically improved after a single dose of thiamine.
Topics: Aged, 80 and over; Beriberi; Disease Progression; Dose-Response Relationship, Drug; Electrocardiogra | 2014 |
Progressive encephalopathy associated with nutritional deficiencies: Identifying patients at high risk for developing thiamine deficiency.
Topics: Acidosis; Acute Kidney Injury; Delayed Diagnosis; Disease Progression; Duodenitis; Female; Gait Diso | 2017 |
Hearing and seeing: Unusual early signs of Wernicke encephalopathy.
Topics: Adult; Colectomy; Crohn Disease; Disease Progression; Early Diagnosis; Female; Humans; Inferior Coll | 2008 |
Intracerebral haemorrhage in a malnourished patient, related to Wernicke's encephalopathy.
Topics: Adult; Anemia; Black People; Brain; Cerebral Arteries; Cerebral Hemorrhage; Disease Progression; Fem | 2008 |
Neurodegeneration in thiamine deficient rats-A longitudinal MRI study.
Topics: Analysis of Variance; Animals; Anisotropy; Brain Mapping; Diffusion Tensor Imaging; Disease Progress | 2010 |
Can an enzyme cofactor be a factor in malignant progression?
Topics: Cell Hypoxia; Coenzymes; Disease Progression; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Mem | 2010 |
[Sensorineural hearing loss: New prospects for therapy].
Topics: Adjuvants, Immunologic; Administration, Oral; Aged; Audiometry; Disease Progression; Dose-Response R | 2011 |
Evolution of abnormal eye movements in Wernicke's encephalopathy: correlation with serial MRI findings.
Topics: Adult; Ataxia; Disease Progression; Eye Movements; Female; Humans; Leukemia, Myeloid, Acute; Magneti | 2012 |
Cerebrospinal fluid levels of thiamine in patients with Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Chromatography, High Pressure Liquid; Disease Progressio | 2002 |
[Guillain-Barre syndrome in children: experience in the neurology service of Dakar].
Topics: Adolescent; Age Distribution; Child; Child, Preschool; Disease Progression; Female; Guillain-Barre S | 2000 |
Postgastrectomy polyneuropathy with thiamine deficiency.
Topics: Activities of Daily Living; Adult; Aged; Biopsy; Diagnosis, Differential; Disease Progression; Femal | 2001 |